Capricor Therapeutics Inc [CAPR] stock is trading at $21.65, up 26.83%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CAPR shares have gain 117.59% over the last week, with a monthly amount glided 410.61%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Capricor Therapeutics Inc [NASDAQ: CAPR] stock has seen the most recent analyst activity on May 17, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $14. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on January 05, 2024, and set its price target to $8. On October 26, 2022, Ladenburg Thalmann initiated with a Buy rating and assigned a price target of $15 on the stock. Maxim Group downgraded its rating to a Hold. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $8.60 on January 26, 2018. H.C. Wainwright reiterated a Buy rating for this stock on September 15, 2017, and upped its price target to $6.50.
Capricor Therapeutics Inc [CAPR] stock has fluctuated between $2.68 and $18.14 over the past year. Currently, Wall Street analysts expect the stock to reach $26.67 within the next 12 months. Capricor Therapeutics Inc [NASDAQ: CAPR] shares were valued at $21.65 at the most recent close of the market. An investor can expect a potential return of 23.19% based on the average CAPR price forecast.
Analyzing the CAPR fundamentals
Capricor Therapeutics Inc [NASDAQ:CAPR] reported sales of 27.15M for the trailing twelve months, which represents a growth of 1.38%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -1.1%, Pretax Profit Margin comes in at -1.03%, and Net Profit Margin reading is -1.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.73, Equity is -2.2 and Total Capital is -1.87. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.78 points at the first support level, and at 15.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.25, and for the 2nd resistance point, it is at 24.85.
Ratios To Look Out For
For context, Capricor Therapeutics Inc’s Current Ratio is 1.37. Further, the Quick Ratio stands at 1.37, while the Cash Ratio is 0.48. Considering the valuation of this stock, the price to sales ratio is 25.95, the price to book ratio is 60.20.
Transactions by insiders
Recent insider trading involved Nippon Shinyaku Co Ltd, 10% Owner, that happened on Sep 20 ’24 when 2.8 million shares were purchased. Director, Musket David B completed a deal on Oct 12 ’23 to buy 410.0 shares. Meanwhile, Director COLLIER EARL M JR bought 10000.0 shares on Oct 10 ’23.
